叶酸
福尔菲里
医学
奥沙利铂
伊立替康
内科学
养生
结直肠癌
胃肠病学
精确检验
化疗
癌症
肿瘤科
作者
Jingmei Liu,Chenshan Yuan,Yongjing Chen,Pijun Ji,Wei Bai
出处
期刊:Cancer Research and Clinic
[Chinese Medical Association]
日期:2017-11-28
卷期号:29 (11): 740-744
标识
DOI:10.3760/cma.j.issn.1006-9801.2017.11.005
摘要
Objective
To observe the effect of two different chemotherapy regimens, including irinotecan, folinic acid and FU chemotherapy regimen (FOLFIRI) versus folinic acid, FU and oxaliplatin chemotherapy regimen (mFOLFOX6) on nutritional status in patients with advanced colon cancer.
Methods
A total of 110 patients with advanced colon cancer in Shanxi Cancer Hospital were divided into FOLFIRI(group A) and mFOLFOX6 (group B). To investigate the effect of two different regimens on the patients with advanced colon cancer by toxicity, the traditional methods of nutritional assessment, scored patient-generated subjective global assessment (PG-SGA), nutrition risk screening-2002 (NRS-2002). Shapiro-Wilk was used to detect the normality of small samples, t test was used to analyze measurement data conformed to the normal distribution, Wilcoxon non-parametric test was used to analyze the abnormal distribution data, and enumeration data was detected by using chi-square test.
Results
The incidence of vomiting, diarrhea and alopecia in group A and group B was respectively 53.8% (28/52) vs. 29.3% (17/58), 65.4% (34/52) vs. 43.1% (25/58), 46.2% (24/52) vs. 20.7% (12/58) respectively, and there was a significant difference (all P 0.05).
Conclusions
FOLFIRI and mFOLFOX6 scheme can reduce the patient's nutritional status. The probability of gastrointestinal adverse reaction of FOLFIRI regimen is high, which may have an obvious impact on nutritional status of patients compared with mFOLFOX6 scheme.
Key words:
Advanced colon cancer; Antineoplastic combined chemotherapy protocols; Nutritional status
科研通智能强力驱动
Strongly Powered by AbleSci AI